KYMR vs. ROIV: Kymera Therapeutics vs. Roivant Sciences Stock Comparison

November 11, 2026

How do Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV)
Profile Item	KYMR	ROIV
Name	Kymera Therapeutics Inc.	Roivant Sciences Ltd.
Country/Region	United States	United Kingdom
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	11.25 billion USD	28.08 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	August 21, 2020	December 8, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

KYMR

ROIV

GSPC

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV)
Metric	KYMR	ROIV
Total Return (1Y)	131.52%	96.75%
Total Return (3Y, Annualized)	111.65%	68.04%
Total Return (5Y, Annualized)	15.68%	36.73%

Risk Profile

Drawdown History

KYMR

ROIV

GSPC

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV)
Metric	KYMR	ROIV
Volatility (1Y, Annualized)	62.83%	47.99%
Beta (5Y)	2.00	1.17
Max Drawdown (5Y)	-83.27%	-79.22%
Avg. Volume (3M)	833.05K	7.82M

Risk-Adjusted Performance

Risk-Return Positioning

KYMR and ROIV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV)
Metric	KYMR	ROIV
Sharpe Ratio (1Y)	2.03	1.93
Sortino Ratio (1Y)	4.16	4.03

Profitability

ROE (TTM)

Both Kymera Therapeutics (KYMR) at -27.29% and Roivant Sciences (ROIV) at -8.52% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
KYMR: -27.29%
Q1: -64.05%
Min: -167.77%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max: 109.18%
Q3: 6.23%
ROIV: -8.52%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Kymera Therapeutics (KYMR) at 0.00% and Roivant Sciences (ROIV) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
KYMR: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
ROIV: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Kymera Therapeutics (KYMR) at -396.04% and Roivant Sciences (ROIV) at -25,408.11% report negative operating margin values, usually indicating operating losses over the period.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
KYMR: -396.04%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
ROIV: -25,408.11%

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV)
Metric	KYMR	ROIV
ROE (TTM)	-27.29%	-8.52%
ROA (TTM)	-17.64%	-16.28%
Net Margin (TTM)	0.00%	0.00%
Operating Margin (TTM)	-396.04%	-25,408.11%
Gross Margin (TTM)	0.00%	0.00%

Growth

Revenue Growth

Both Kymera Therapeutics (KYMR) at -16.70% and Roivant Sciences (ROIV) at -71.57% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Kymera Therapeutics (KYMR) nor Roivant Sciences (ROIV) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV)
Metric	KYMR	ROIV
Revenue Growth (YoY)	-16.70%	-71.57%
Revenue Growth (3Y CAGR)	-5.74%	-36.01%
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max: 25.13
Q3: 12.13
KYMR: 11.13
Median: 5.52
Q1: 2.47
Min: 0.10

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max: 25.13
ROIV: 16.72
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Kymera Therapeutics (KYMR) at 0.05 and Roivant Sciences (ROIV) at 0.02 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max: 1.42
Q3: 0.65
Median: 0.15
KYMR: 0.05
Q1: 0.02
Min: 0.00

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max: 1.42
Q3: 0.65
Median: 0.15
ROIV: 0.02
Q1: 0.02
Min: 0.00

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV)
Metric	KYMR	ROIV
Current Ratio (MRQ)	11.13	16.72
Debt / Equity (MRQ)	0.05	0.02
Net Debt / EBITDA	--	--

Dividends

Dividend Yield (TTM)

Neither Kymera Therapeutics (KYMR) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV)
Metric	KYMR	ROIV
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Roivant Sciences (ROIV) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
KYMR: --

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
ROIV: --

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Investors are paying well above the peer range per dollar of sales for both Kymera Therapeutics (KYMR) at 110.00 and Roivant Sciences (ROIV) at 3,728.61 — each P/S ratio clears its industry’s benchmark range.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR: 110.00
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV: 3,728.61
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both Kymera Therapeutics (KYMR) at 6.96 and Roivant Sciences (ROIV) at 6.64 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max: 13.53
KYMR: 6.96
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max: 13.53
ROIV: 6.64
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Kymera Therapeutics (KYMR) vs. Roivant Sciences (ROIV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Kymera Therapeutics (KYMR) and Roivant Sciences (ROIV)
Metric	KYMR	ROIV
P/E Ratio (TTM)	--	--
P/S Ratio (TTM)	110.00	3,728.61
P/B Ratio (MRQ)	6.96	6.64
Free Cash Flow Yield (TTM)	-1.46%	-3.98%